The 340B Drug Discount Program: Why More Transparency Will Help Low-Income Communities

The federal 340B Drug Pricing Program is currently a focus of oversight efforts by Congress. In a new post, the University of Chicago’s Rena M. Conti explains why greater transparency is needed for the program, which requires drug manufacturers to provide discounted outpatient drugs to qualified health care facilities serving low-income patients.